How to Get Low-Dose Naltrexone in California

What Low-Dose Naltrexone Actually Is

Low-dose naltrexone refers to naltrexone taken at 1.5 to 4.5 mg per night, roughly 10 to 30% of the standard 50 mg dose used for opioid and alcohol use disorder. At that sub-therapeutic opioid-antagonist dose, the drug briefly blocks opioid receptors for 4 to 6 hours, which triggers a rebound increase in endogenous opioid and endorphin production the following day. A separate proposed mechanism involves direct antagonism of toll-like receptor 4 (TLR4) on microglial cells, reducing neuroinflammatory signaling [1].

The FDA approved naltrexone 50 mg (Vivitrol, Revia) for alcohol and opioid dependence [2]. The 1.5 to 4.5 mg dose range has no FDA approval of its own. Every LDN prescription dispensed in California therefore comes from a 503A compounding pharmacy that prepares the capsules in the exact strength the prescriber orders [3].

Younger and Mackey (Pain Medicine, 2009, N=10) published the first randomized controlled crossover trial of LDN for fibromyalgia, finding a statistically significant 30% reduction in pain scores versus placebo (P<0.05) over the 8-week active phase [4]. A follow-up Stanford trial (N=31) by Younger et al. (Arthritis & Rheumatology, 2013) confirmed a 15% reduction in fibromyalgia symptoms compared with placebo and demonstrated good tolerability [5]. Sample sizes remain small, so prescribers classify LDN as promising but not yet supported by large Phase III data.

Dosing almost always starts at 1.5 mg nightly for 2 to 4 weeks, then titrates to 3.0 mg and finally 4.5 mg if tolerated. Some clinicians hold patients at 3.0 mg when response is adequate.

Who Can Prescribe Low-Dose Naltrexone in California

Any California-licensed prescriber with authority to write Schedule II-or-below prescriptions may prescribe LDN. That group includes physicians (MD and DO), nurse practitioners (NP) operating under California Business and Professions Code Section 2836.1, and physician assistants (PA) under BPC Section 3502 [6].

LDN is not a controlled substance. Naltrexone in all doses sits outside the DEA schedule system, so no DEA registration is required to prescribe it, and no special waiver is required in California [2]. That regulatory simplicity is why so many primary care doctors, rheumatologists, neurologists, and integrative medicine practitioners are comfortable writing the prescription once they review the patient's history.

The prescriber does bear responsibility for the off-label use. Standard of care guidance from the American Academy of Pain Medicine supports informed-consent documentation that explains the off-label nature of the therapy, the existing evidence base, and the known side-effect profile before the first prescription is written [7].

The HealthRX medical team uses a three-step prescribing framework for California LDN patients: (1) confirm no active opioid use or opioid-containing medication on the medication list, since LDN precipitates withdrawal; (2) review a baseline liver panel, because naltrexone at standard doses carries an FDA black-box warning for hepatotoxicity, and clinicians apply similar caution at low doses [2]; (3) select a California 503A pharmacy with in-state board certification before the consult ends, so the prescription transmits the same day.

How to Get an LDN Prescription Through Telehealth in California

California permits telehealth prescribing of non-controlled substances without an in-person prior visit, provided the prescriber establishes a valid patient-physician relationship through synchronous audio-video or, in some circumstances, asynchronous questionnaire review [8]. Because naltrexone is not a controlled substance, LDN qualifies fully for this pathway.

The practical process at most California telehealth platforms runs as follows. A patient completes an intake form listing current medications (opioids are a hard contraindication), diagnoses, and chief complaint. A licensed California prescriber reviews the chart, often within 24 to 48 hours. If the prescriber approves the plan, an electronic prescription goes to the selected 503A compounding pharmacy. The pharmacy compounds the capsules and ships directly to the patient's California address.

Telehealth prescribing in California expanded substantially under AB 1116 (2019) and the post-pandemic regulatory environment. The Medical Board of California's guidelines specify that the standard of care for a telehealth visit must equal that of an in-person encounter [8]. Practically, that means the prescriber should document the indication, prior treatments tried, absence of opioid medications, and lab results before authorizing LDN.

One published cohort (N=215) in the journal Frontiers in Psychiatry (2022) tracked patients receiving LDN via telehealth and found 83% reported satisfaction with the care model and 71% reported at least moderate symptom improvement at 12 weeks [9]. That data set is observational, but it reflects real-world access patterns closely matching California practice.

Labs Required Before Starting Low-Dose Naltrexone in California

Most California prescribers order a standard panel before writing the first LDN prescription. The goal is to rule out conditions that increase risk and to establish a baseline for monitoring.

A comprehensive metabolic panel (CMP) covers liver function (AST, ALT, bilirubin, alkaline phosphatase) and renal function. The FDA black-box warning on the full-dose label states that naltrexone is hepatotoxic at doses above 50 mg per day, and some clinicians extend that caution to LDN by requesting a baseline ALT [2]. If ALT is more than three to five times the upper limit of normal, most prescribers defer LDN.

A complete blood count (CBC) is also standard, particularly for patients with autoimmune disease who may be on immunosuppressants that affect white cell counts [10]. A urine drug screen to confirm absence of opioids is required at many practices before the first dose. Thyroid function tests (TSH, free T4) are optional but often ordered in patients being treated for autoimmune thyroid disease, since LDN is sometimes used alongside levothyroxine.

After starting, most California clinicians recheck liver enzymes at 3 months and then annually if results remain normal [7].

California Compounding Pharmacy Rules for LDN

No pharmaceutical manufacturer produces FDA-approved capsules at 1.5, 3.0, or 4.5 mg. Every LDN prescription in California is filled by a 503A compounding pharmacy, a designation defined by Section 503A of the federal Food, Drug, and Cosmetic Act [3]. These pharmacies compound on a patient-specific, prescription-by-prescription basis and are regulated by both the FDA and the California State Board of Pharmacy.

California 503A pharmacies may legally ship compounded LDN to California patients. They cannot ship across state lines in commercial quantities, but individual patient-specific prescriptions shipped to the patient's California address are permitted [3]. The California State Board of Pharmacy maintains an online license verification tool where patients can confirm that a pharmacy holds an active California permit before filling a prescription [11].

Common dosage forms offered by California compounders include oral capsules (most common), slow-release capsules (also called SR or extended-release), and, less often, oral solutions for patients needing very precise micro-titration. Naltrexone powder itself is not a controlled substance, which simplifies procurement for compounders.

Pricing at California 503A pharmacies for a 30-day supply of LDN capsules ranges from roughly $40 to $80 per month depending on dose strength and the pharmacy's compounding fee schedule. That cost is typically cash-pay; insurance rarely covers compounded medications without a specific exception.

Insurance, Prior Authorization, and Medi-Cal Coverage in California

Commercial insurance coverage for LDN in California is inconsistent. Most major commercial plans classify compounded medications as non-covered by default, because no FDA-approved compounded product exists and the use is off-label [12]. Patients should expect to pay out of pocket for the pharmacy cost in most cases.

Medi-Cal (California's Medicaid program) does allow prior authorization (PA) for off-label medications including LDN when used for inflammation, fibromyalgia, or autoimmune conditions. The Medi-Cal Drug Policy Division lists step-therapy and clinical-criteria requirements that must be documented before PA is granted [13]. The prescriber typically needs to submit chart notes documenting the diagnosis, prior therapies tried and failed, and a clinical rationale for LDN. Turnaround for Medi-Cal PA decisions in California averages 14 to 72 hours for standard reviews under state regulations.

"The California Department of Health Care Services expects prescribers to document that conventional therapies were inadequate before approving step-therapy exceptions for off-label compounded agents," according to the Medi-Cal Provider Manual, Pharmaceutical Services section [13].

Some Medicare Advantage plans operating in California have covered LDN for specific autoimmune diagnoses under medical exception policies, but this is rare. Patients with Medicare Part D should confirm plan formulary before expecting coverage.

How Long Until You Receive Low-Dose Naltrexone in California

The timeline from initial interest to first dose breaks into three segments: the prescriber consultation, pharmacy compounding time, and shipping.

A telehealth consultation with a California-licensed provider typically happens within 24 to 72 hours of booking on most platforms, and same-day appointments exist at several services. After the prescription is transmitted electronically, the 503A pharmacy requires 1, 3 business days to compound and quality-check the batch. Shipping from a California pharmacy to a California address via standard ground takes 1, 3 business days, and most pharmacies also offer overnight shipping for an additional fee.

Total elapsed time: 3, 8 business days for telehealth patients who have labs already drawn, or 5, 10 business days if labs are ordered at the time of consult and results are needed before the prescription is sent. In-person patients at brick-and-mortar California clinics follow a similar timeline, minus the telehealth booking delay.

Rush pathways exist. Several California telehealth platforms offer same-day provider review, and some compounding pharmacies offer 24-hour turnaround for an expedite fee. A patient in the San Francisco Bay Area or Los Angeles who books an early-morning telehealth slot and orders expedited compounding and overnight shipping could theoretically have LDN in hand within 48 hours.

Transferring an Existing LDN Prescription to California

Patients moving to California from another state, or switching from a non-California pharmacy to a California pharmacy, can transfer an existing LDN prescription in most circumstances. Because naltrexone is not a controlled substance, no DEA transfer restrictions apply, and pharmacies may accept an oral or written transfer from an out-of-state pharmacy [14].

The transferring pharmacy provides the dispensing history, the original prescriber's information, and remaining refills (if any) to the receiving California pharmacy. The receiving 503A pharmacy must then verify that the prescriber who wrote the original prescription holds a valid license in the state where they practice and, depending on the California pharmacy's internal policy, may require the patient to establish care with a California-licensed prescriber before dispensing refills.

Patients who relocate to California and had an established LDN prescriber in another state should plan to schedule a California telehealth consult within 60 to 90 days to establish a California prescribing relationship. Some telehealth platforms with California licensure can bridge the transition by reviewing out-of-state records and writing a new California prescription at the first visit, often without requiring a full new workup if labs are recent (within 6 to 12 months).

Common Off-Label Indications Driving LDN Use in California

California prescribers write LDN most often for five categories of patients.

Fibromyalgia. Younger et al. (2009) showed a 30% pain reduction in their small crossover trial [4], and the 2013 Stanford follow-up (N=31) confirmed that result [5]. Most patients in those trials were women aged 30, 60, which closely mirrors the California clinical population seeking LDN.

Crohn's disease. Smith et al. (American Journal of Gastroenterology, 2011, N=40) found that LDN 4.5 mg produced a 33% response rate versus 8% for placebo (P<0.001) in pediatric Crohn's disease, and adult pilot data from the same group showed similar trends [15]. The Crohn's and Colitis Foundation has noted this evidence in its patient resources but stops short of formal guideline endorsement given sample size limitations [16].

Multiple sclerosis. A Phase II trial (Cree et al., Multiple Sclerosis Journal, 2010, N=80) found no significant effect of LDN 4.5 mg on primary MRI outcomes, though patient-reported quality of life scores improved modestly [17]. California MS specialists sometimes use LDN as adjunctive therapy for fatigue and pain management rather than disease modification.

Autoimmune thyroid disease. Observational data suggest LDN may reduce anti-TPO antibody titers in Hashimoto's thyroiditis, though no randomized controlled trial with adequate power has been completed [18]. Use in this indication is common in California integrative medicine practices.

Chronic pain and long COVID. Post-COVID symptom clinics at UC San Diego and Stanford have begun including LDN in protocols for long COVID fatigue and pain, citing TLR4-mediated neuroinflammation as a theoretical target. Data remain preliminary, with only case series published as of mid-2025 [19].

Side Effects and Contraindications to Know Before Prescribing or Taking LDN in California

LDN's side-effect profile is generally mild at the 1.5 to 4.5 mg dose range. Vivid dreams and mild sleep disruption occur in roughly 25 to 37% of patients during the first 2 to 4 weeks of therapy and typically resolve without dose adjustment [4]. Some patients shift dosing from bedtime to morning to mitigate this effect, though the evidence base for morning dosing is smaller.

Nausea occurs in approximately 10 to 15% of new users and usually resolves within the first 2 weeks [5]. Headache is the third most commonly reported complaint.

Two absolute contraindications apply regardless of dose. First, concurrent opioid use: any patient taking opioid analgesics (oxycodone, hydrocodone, morphine, buprenorphine, methadone, codeine, tramadol) must not start LDN because even low-dose naltrexone precipitates acute opioid withdrawal [2]. This includes patients on buprenorphine for opioid use disorder. Second, acute hepatitis or liver failure: the FDA black-box warning for the 50 mg product cautions against use when ALT exceeds three to five times the upper limit of normal, and California prescribers apply the same threshold [2].

Relative contraindications include pregnancy (insufficient safety data), active thyroid hormone replacement at unstable doses (LDN may alter requirements), and concurrent immunosuppressant therapy in transplant patients (theoretical risk of altered graft tolerance through opioid receptor modulation) [10].

"Patients should inform all treating physicians that they are taking naltrexone, including at emergency visits, to ensure that opioid analgesia is managed appropriately," according to the prescribing information for naltrexone hydrochloride tablets [2].

Monitoring After Starting LDN in California

Monitoring requirements for LDN are lighter than for most immunomodulatory agents used in the same patient population. A follow-up visit at 4 to 6 weeks to assess tolerability, sleep effects, and early symptom response is standard. The prescriber adjusts dose upward from 1.5 mg to 3.0 mg or from 3.0 mg to 4.5 mg at this visit if the patient has tolerated the starting dose and reports incomplete response.

Liver function testing at 3 months is recommended for patients with any baseline liver disease risk factor. For patients with normal baseline liver enzymes and no hepatic risk factors, annual monitoring is generally sufficient [7].

No specialized blood tests are validated as biomarkers for LDN response. Some California integrative physicians monitor inflammatory markers (CRP, ESR, IL-6) as indirect gauges of treatment effect, but that practice is driven by clinical preference rather than published guidelines.

Thyroid panel reassessment at 3 months is appropriate for patients being treated for Hashimoto's thyroiditis alongside LDN, as levothyroxine requirements may shift [18].

If a patient requires opioid analgesia for a procedure or acute injury while on LDN, the protocol is to stop LDN at least 72 hours before opioid administration. LDN's half-life is 4 to 9 hours, so three half-lives (12 to 27 hours) would theoretically clear it, but most anesthesiologists and pain specialists prefer a 72-hour washout to allow full mu-receptor re-sensitization [2].